Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi's Biosimilars Deal With JHL Confirms Growing Trend In China

Executive Summary

Sanofi is joining the biosimilars trend to tap into China through a local partnership with Taiwan's JHL Biotech, initially focusing on rituximab, a biosimilar product that has great market potential but strong competition in development by domestic peers.

You may also be interested in...



Three-Decades Tenure But No Loyalty: Genentech Scientist Charged With Biosimilar Trade Secrets Theft

Government indicts former Genentech employees, one of whom admits to secretly working at JHL Biotech and downloading confidential documents. Trade secrets theft case is unusual in two ways: its extraordinary scope and detail and the filing of criminal charges.

Three-Decades Tenure But No Loyalty: Genentech Scientist Charged With Biosimilar Trade Secrets Theft

Government indicts former Genentech employees, one of whom admits to secretly working at JHL Biotech and downloading confidential documents. Trade secrets theft case is unusual in two ways: its extraordinary scope and detail and the filing of criminal charges.

Sanofi’s Keeney On Early-Stage Assets, 'Open Dialogue' With Asian Start-Ups

Dr. Adam Keeney, Global Head, External Innovation and R&D Strategy at Sanofi, outlines in an interview with Scrip the company’s interest in early-stage assets and intent to tap into opportunities in Asia-Pacific. He also discusses the region’s role as a digital hub.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel